Boehringer Ingelheim Offers a Licence to Apotex to Export BI's patented product nevirapine to Developing Countries
Boehringer Ingelheim has offered the Canadian generic pharmaceutical manufacturer Apotex Inc. a royalty free, voluntary licence to manufacture and export products containing nevirapine to Rwanda as requested by Apotex. Boehringer Ingelheim has also offered to extend the license to other developing countries as identified by the World Health Organization.
"This licence is one part of Boehringer Ingelheim's ongoing commitment to provide access to nevirapine in the developing world," states President and CEO of Boehringer Ingelheim (Canada) Ltd. Ian Mills. "For example, through its Viramune Donation Program for the Prevention of Mother-To-Child Transmission, Boehringer Ingelheim currently donates nevirapine to close to 60 countries to help prevent the transmission of HIV to new born children."
If Apotex accepts the voluntary licence, it will be free to manufacture product containing nevirapine for export to the developing world to help those patients suffering from HIV/AIDS. The terms of the licence offer are more favourable terms than those required under the access to medicines provisions of Canadian Legislation.
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.